Clinical and pathological characteristics of patients with double expressor diffuse large B-cell lymphomas (DLBCLs) not otherwise specified (NOS), diagnosed at Hospital San José de Bogotá, Colombia
DOI:
https://doi.org/10.17533/udea.iatreia.181Keywords:
Immunohistochemistry, Lymphoma Large B-Cell Diffuse, Lymphoma Non-Hodgkin, Hystology, RituximabAbstract
Introduction: Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS) with MYC and BCL2 overexpression by immunohistochemistry constitutes the double expressor group, which has been associated with worse outcomes compared to non-double expressor DLBCL. There is limited research on the clinical behavior of double expressor DLBCL NOS in the region.
Objectives: To determine the clinical and pathological characteristics, as well as response rates, in patients diagnosed with double expressor DLBCL NOS at Hospital de San Jose in Bogota.
Methods: Observational retrospective cohort study including patients with DLBCL NOS diagnosed at Hospital de San Jose between 2016 and 2019. Central pathology review was performed to confirm the diagnosis, assess cellular morphology, and evaluate MYC and BCL2 expression.
Results: A total of 67 patients with DLBCL NOS were included. 49.3% of the cases originated from the germinal center and 33 cases were classified as double expressor (49.2%). The overall response rate was 42.4% in the double expressor DLBCL NOS group and 76.9% in the total DLBCL NOS population.
Conclusion: Double expressor diffuse large B-cell lymphoma showed lower overall response rates following standard immunochemotherapy. High-risk International Prognostic Index (IPI) was associated with lower rates of complete response.
Downloads
References
(1 Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood [Internet]. 2006 Jan;107(1):265-76. DOI 10.1182/blood-2005-06-2508.
(2) Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med [Internet]. 2021 Mar 4;384(9):842-58. DOI 10.1056/NEJMra2027612.
(3) Laurini JA, Perry AM, Boilesen E, Diebold J, Maclennan KA, Müller-Hermelink HK, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood [Internet]. 2012 Dec 6;120(24):4795-801. DOI 10.1182/blood-2012-07-440073.
(4) Yin X, Xu A, Fan F, Huang Z, Cheng Q, Zhang L, et al. Incidence and Mortality Trends and Risk Prediction Nomogram for Extranodal Diffuse Large B-Cell Lymphoma: An Analysis of the Surveillance, Epidemiology, and End Results Database. Front Oncol [Internet]. 2019 Nov 12;9:1198. DOI 10.3389/fonc.2019.01198.
(5) Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. In World Health Organization Classification of Tumours, 4th ed. Lyon, France: International Agency for Research on Cancer; 2017.
(6) Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol [Internet]. 2012;30:3452-59. DOI 10.1200/JCO.2011.41.0985.
(7) Staiger AM, Ziepert M, Horn H, Scott DW, Barth TF, Bernd HW et al. Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group. J Clin Oncol [Internet]. 2017;35:2515-2526. DOI 10.1200/JCO.2016.70.3660.
(8) Green TM, Nielsen O, De Stricker K, Xu-Monette ZY, Young KH, Møller MB. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol [Internet]. 2012 Apr;36(4):612-9. DOI 10.1097/PAS.0b013e318244e2ba.
(9) Li S, Lin P, Medeiros LJ. Advances in pathological understading of high – grade B cell lymphomas. Expert Rev Hematol [Internet]. 2018;11(8):637-48. DOI 10.1080/17474086.2018.1494567.
(10) Talaulikar D, Dahlstrom JE, Shadbolt B, Broomfield A, McDonald A. Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL). J Histochem Cytochem [Internet]. 2008 Oct;56(10):893-900. DOI 10.1369/jhc.2008.951087.
(11) Combariza JF, Lombana M, Torres AM, Castellanos AM, Arango M. General features and epidemiology of lymphoma in Colombia. A multicentric study. Ann Hematol [Internet]. 2015 Jun;94(6):975-80. DOI 10.1007/s00277-015-2301-7.
(12) Guevara N, Jaramillo PE, Rendón J. Caracterización de factores pronósticos en pacientes con linfoma B difuso de células grandes. Acta Med Colomb [Internet]. 2014;39(2):137-47. Disponible en:
https://www.redalyc.org/articulo.oa?id=163131492009
(13) Younes A, Hilden P, Coiffer B, Hagenbeek A, Salles G, Wilson W et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol [Internet]. 2017 Jul;28(7):1436–47. DOI 10.1093/annonc/mdx097.
(14) Villacruz L, Socinski M. The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res [Internet]. 2013 May 15;19(10):2629-36. DOI 10.1158/1078-0432.CCR-12-2935.
(15) Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol [Internet]. 2012 Oct 1;30(28):3460-7. DOI 10.1200/JCO.2011.41.4342.
(16) Moore EM, Aggarwal N, Surti U, Swerdlow SH. Further Exploration of the Complexities of Large B-Cell Lymphomas with MYC Abnormalities and the Importance of a Blastoid Morphology. Am J Surg Pathol [Internet]. 2017 Sep;41(9):1155-66. DOI 10.1097/PAS.0000000000000818.
(17) Mallick S, Panda A, Lone MR, Goswami A, Ramteke P, Sharma MC et al. Clinicopathological Profile of Primary Double Expressor Lymphoma. Clinical Lymphoma, Myeloma and Leukemia [Internet]. 2019;19:S257. DOI: https://doi.org/10.1016/j.clml.2019.07.169.
(18) Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev [Internet]. 2017 Mar;31(2):37-42. DOI 10.1016/j.blre.2016.09.004.
(19) Di Napoli A, Remotti D, Agostinelli C, Ambrosio MR, Ascani S, Carbone A, et al. Correction to: A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit. Virchows Arch [Internet]. 2019 Oct;475(4):513-8. DOI 10.1007/s00428-019-02637-2.
(20) Hu S, Xu‐Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B‐cell subtype of diffuse large B‐cell lymphoma and demonstrates high‐risk gene expression signatures: a report from the International DLBCL Rituximab‐CHOP Consortium Program. Blood [Internet]. 2013;121(20):4021‐31. DOI 10.1182/blood-2012-10-460063.
(21) Pfreundschuh, M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol [Internet]. 2008;9:105–16 DOI 10.1016/S1470-2045(08)70002-0.
(22) Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med [Internet]. 2002;346(4):235-42 DOI 10.1056/NEJMoa011795.
(23) Riedell P, Smith S. Double hit and double expressors in lymphoma: Definition and treatment. Cancer [Internet]. 2018 Dec 15;124(24):4622-32. DOI 10.1002/cncr.31646.
(24) International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med [Internet]. 1993;329(14):987-94. DOI: 10.1056/NEJM199309303291402.
(25) Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol [Internet]. 2010;28(14):2373-2380. DOI 10.1200/JCO.2009.26.2493.
(26) Ruppert A, Dixon J, Salles G, Wall A, Cunningham D, Poeschel V, et al. International prognostic indices in diffuse large B cell lymphoma: a comparison of IPI, R-IPI and NCCN IPI. Blood [Internet]. 2020;135(23):2041-2048. DOI 10.1182/blood.2019002729.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Iatreia
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
